Brucine, an indole alkaloid from Strychnos nux-vomica attenuates VEGF-induced angiogenesis via inhibiting VEGFR2 signaling pathway in vitro and in vivo

Cancer Letters

Volumn 332, Issue 1, 2013, Pages 83-93

  Saraswati, Sarita ^a   Agrawal, S S ^b  

^a DELHI INSTITUTE OF PHARMACEUTICAL SCIENCES AND RESEARCH   (India)

^b AMITY UNIVERSITY   (India)

Author keywords

Angiogenesis; Matrigel; Signaling; Vascular endothelial growth factor receptor 2

Indexed keywords

ANTINEOPLASTIC AGENT; AVASTATIN; BEVACIZUMAB; BRUCINE; FOCAL ADHESION KINASE 1; GAMMA INTERFERON; INDOLE; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; PLANT EXTRACT; PROTEIN KINASE; SORAFENIB; STEROID RECEPTOR COACTIVATOR 1; STRYCHNOS NUX VOMICA EXTRACT; SUNITINIB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN C;

ANGIOGENESIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLEEDING; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; DIGESTIVE SYSTEM PERFORATION; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; MALE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; RAT; STRYCHNOS NUX VOMICA; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, EHRLICH TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CHEMOTAXIS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; PHOSPHORYLATION; PLANTS, MEDICINAL; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SIGNAL TRANSDUCTION; STRYCHNINE; STRYCHNOS NUX-VOMICA; TIME FACTORS; TISSUE CULTURE TECHNIQUES; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

STRYCHNOS NUX-VOMICA;

EID: 84875270769     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.01.012     Document Type: Article

References (50)

1. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2002, 2:727-739.
2. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
3. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
4. Ferrara N. VEGF and the quest for tumor angiogenesis factors. Nat. Rev. Cancer 2002, 2:795-803.
5. Schlessinger J. New roles for Src kinases in control of cell survival and angiogenesis. Cell 2000, 100:293-296.
6. Qi J.H., Claesson-Welsh L. VEGF-induced activation of phosphoinositide 3-kinase is dependent on focal adhesion kinase. Exp. Cell Res. 2001, 263:173-182.
7. Cho C.H., Lee C.S., Chang M., Jang I.H., Kim S.J., Hwang I., et al. Localization of VEGFR-2 and PLD2 in endothelial caveolae is involved in VEGF-induced phosphorylation of MEK and ERK. Am. J. Physiol. Heart Circ. Physiol. 2004, 286:H1881-H1888.
8. Kim B.W., Choi M., Kim Y.S., Park H., Lee H.R., Yun C.O., et al. Vascular endothelial growth factor (VEGF) signaling regulates hippocampal neurons by elevation of intracellular calcium and activation of calcium/calmodulin protein kinase II and mammalian target of rapamycin. Cell Signal. 2008, 20:714-725.
9. Baek J.H., Jang J.E., Kang C.M., Chung H.Y., Kim N.D., Kim K.W. Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene 2000, 19:4621-4631.
10. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004, 9:2-10.
11. Holash J., Davis S., Papadopoulos N., Croll S.D., Ho L., Russell M., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA 2002, 99:11393-11398.
12. Noble M.E., Endicott J.A., Johnson L.N. Protein kinase inhibitors: insights into drug design from structure. Science 2004, 303:1800-1805.
13. Kamba T., McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer 2007, 96:1788-1795.
14. Agrawal S.S., Saraswati S., Mathur R., Pandey M. Cytotoxic and antitumor effects of brucine on Ehrlich ascites tumor and human cancer cell line. Life Sci. 2011, 89:147-158.
15. Cai B.C., Wang T.S., Kurokawa M., Shiraki K., Hattori M. Cytotoxicities of alkaloids from processed and unprocessed seeds of Strychnos nux-vomica. Acta Pharm. Sinic. 1998, 19:425-428.
16. Rao P.S., Ramanadham M., Prasad M.N. Anti-proliferative and cytotoxic effects of Strychnos nux-vomica root extract on human multiple myeloma cell line-RPMI 8226. Food Chem. Toxicol. 2009, 47:283-288.
17. Agrawal S.S., Saraswati S., Mathur R., Pandey M. Brucine, a plant derived alkaloid inhibits inflammatory angiogenesis in a murine sponge model. Biomed. Prev. Nutr. 2011, 1:180-185.
18. Tang J.Y., Li S., Li Z.H., Zhang Z.J., Hu G., Cheang L.C., et al. Calycosin promotes angiogenesis involving estrogen receptor and mitogen-activated protein kinase (MAPK) signaling pathway in zebrafish and HUVEC. PLoS One 2010, 5:e11822.
19. Nicosia R.F., Ottinetti A. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab. Invest. 1990, 63:115-122.
20. Passaniti A., Taylor R.M., Pili R., Guo Y., Long P.V., Haney J.A., et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest. 1992, 67:519-528.
21. Agrawal S.S., Saraswati S., Mathur R., Pandey M. Antitumor properties of Boswellic acid against Ehrlich ascites cells bearing mouse. Food Chem. Toxicol. 2011, 49:1924-1934.
22. Shibuya M. Vascular endothelial growth factor (VEGF)-receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E. Endothelium 2006, 13:63-69.
23. Klagsbrun M., D'Amore P.A. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev. 1996, 7:259-270.
24. Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am. J. Physiol. Cell Physiol. 2001, 280:C1375-C1386.
25. Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., Mol M., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 2001, 7:575-583.
26. Ferrara N., Gerber H.P., Le Couter J. The biology of VEGF and its receptors. Nat. Med. 2003, 9:669-676.
27. Pang X., Yi Z., Zhang J., Lu B., Sung B., Qu W., et al. Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res. 2010, 70:1951-1959.
28. Edirisinghe I., Yang S.R., Yao H., Rajendrasozhan S., Caito S., Adenuga D., et al. VEGFR2 inhibition augments cigarette smoke-induced oxidative stress and inflammatory responses leading to endothelial dysfunction. FASEB J. 2008, 22:2297-2310.
29. Olsson A.K. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 2006, 7:359-371.
30. Gerber H.P., McMurtrey A., Kowalski J., Yan M., Keyt B.A., Dixit V., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway, requirement for Flk-1/KDR activation. J. Biol. Chem. 1998, 273:30336-30343.
31. Parenti A., Morbidelli L., Cui X.L., Douglas J.G., Hood J.D., Granger H.J., et al. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase1/2 activation in postcapillary endothelium. J. Biol. Chem. 1998, 273:4220-4226.
32. Verheul H.M., Salumbides B., Van Erp K., Hammers H., Qian D.Z., Sanni T., et al. Combination strategy targeting the hypoxia inducible factor-1α with mammalian target of rapamycin and histone deacetylase inhibitors. Clin. Cancer Res. 2008, 144:3589-3597.
33. García-Maceira P., Mateo J. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signaling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene 2009, 28:313-324.
34. Wouters B.G., Koritzinsky M. Hypoxia signaling through mTOR and the unfolded protein response in cancer. Nat. Rev. Cancer 2008, 8:851-864.
35. Liu B., Faia L., Hu M., Nussenblatt R.B. Pro-angiogenic effect of IFNγ is dependent on the PI3K/mTOR/translational pathway in human retinal pigmented epithelial cells. Mol. Vis. 2010, 16:184-193.
36. Pober J.S., Sessa W.C. Evolving functions of endothelial cells in inflammation. Nat. Rev. 2007, 7:803-815.
37. Dvorak H.F., Nagy J.A., Feng D., Brown L.F., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 1999, 237:97-132.
38. Zachary I. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc. Res. 2001, 49:568-581.
39. Shiojima I., Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ. Res. 2002, 90:1243-1250.
40. Liu J., Agarwal S. Mechanical signals activate vascular endothelial growth factor receptor-2 to upregulate endothelial cell proliferation during inflammation. J. Immunol. 1855, 2012:1215-1221.
41. Eliceiri B.P., Puente X.S., Hood J.D., Stupack D.G., Schlaepfer D.D., Huang X.Z., et al. Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J. Cell Biol. 2002, 157:149-160.
42. Chou M.T., Wang J., Fujita D.J. Src kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells. BMC Biochem. 2002, 3:32.
43. Ali N., Yoshizumi M., Fujita Y., Izawa Y., Kanematsu Y., Ishizawa K., et al. A novel Src kinase inhibitor, M475271, inhibits VEGF-induced human umbilical vein endothelial cell proliferation and migration. J. Pharmacol. Sci. 2005, 98:130-141.
44. Mitra S.K., Schlaepfer D.D. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr. Opin. Cell Biol. 2006, 18:516-523.
45. Avraham H.K., Lee T.H., Koh Y., Kim T.A., Jiang S., Sussman M., et al. Vascular endothelial growth factor regulates focal adhesion assembly in human brain microvascular endothelial cells through activation of the focal adhesion kinase and related adhesion focal tyrosine kinase. J. Biol. Chem. 2003, 278:36661-36668.
46. Holmqvist K., Cross M.J., Rolny C., Hägerkvist R., Rahimi N., Matsumoto T., et al. The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J. Biol. Chem. 2004, 279:22267-22275.
47. Matsuo M., Yamada S., Koizumi K., Sakurai H., Saiki I. Tumor-derived fibroblast growth factor-2 exerts lymphangiogenic effects through Akt/mTOR/p70S6kinase pathway in rat lymphatic endothelial cells. Eur. J. Cancer 2007, 43:1748-1754.
48. Li W., Tan D., Zhang Z., Liang J.J., Brown R.E. Activation of Akt-mTOR-p70S6K pathway in angiogenesis in hepatocellular carcinoma. Oncol. Rep. 2008, 20:713-719.
49. Bhat T.A., Singh R.P. Tumor angiogenesis - a potential target in cancer chemoprevention. Food Chem. Toxicol. 2008, 46:1334-1345.
50. Cao Y., Liu Q. Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis. Adv. Cancer Res. 2007, 97:203-224.